Intelligence Feed event · Equity · 2026-10-01

    Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data

    Question

    Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data

    Direct answer

    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial established that adding oncolytic adenovirus VCN-01 to standard-of-care chemotherapy generated improvements in overall survival, progression-free survival, and response duration for patients with metastatic pancreatic cancer, setting up Phase 3 development discussions.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-publishes-positive-phase-2b-pancreatic-cancer-data-ec98bf

    EQUITY
    Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial established that adding oncolytic adenovirus VCN-01 to standard-of-care chemotherapy generated improvements in overall survival, progression-free survival, and response duration for patients with metastatic pancreatic cancer, setting up Phase 3 development discussions.
    TOVX
    Impact
    69
    OCT 1
    SIG
    88%
    TOVX
    Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer Data
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial established that adding oncolytic adenovirus VCN-01 to standard-of-care chemotherapy generated improvements in overall survival, progression-free survival, and response duration for patients with metastatic pancreatic cancer, setting up Phase 3 development discussions.
    → Statistically validated Phase 2b oncology data published in Nature Medicine lowers regulatory hurdle risk for VCN-01, lifting TOVX market capitalization.
    Impact
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial established that adding oncolytic adenovirus VCN-01 to standard-of-care chemotherapy generated improvements in overall survival, progression-free survival, and response duration for patients with metastatic pancreatic cancer, setting up Phase 3 development discussions.
    Affected
    TOVX
    Transmission
    Statistically validated Phase 2b oncology data published in Nature Medicine lowers regulatory hurdle risk for VCN-01, lifting TOVX market capitalization.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXbiotech clinical pipeline de-risking via peer-reviewed survival dataUp1-5dNature Medicine publication confirmed improved OS and PFS for VCN-01 in metastatic pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month